Home > Journals > Italian Journal of Dermatology and Venereology > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2010 June;145(3) > Giornale Italiano di Dermatologia e Venereologia 2010 June;145(3):319-22



Publishing options
To subscribe PROMO
Submit an article
Recommend to your librarian





Giornale Italiano di Dermatologia e Venereologia 2010 June;145(3):319-22


language: English

Efficacy of an alpha-hydroxy acid (AHA)-based cream, even in monotherapy, in patients with mild-moderate acne

Baldo A. 1, Bezzola P. 2, Curatolo S. 3, Florio T. 4, Lo Guzzo G. 5, Lo Presti M. 1, Sala G. P. 6, Serra F. 7, Tonin E. 8, Pellicano M. 9, Pimpinelli N. 10

1 Dermatologic Clinic, Napoli Federico II University 2 Private Practitioner in Dermatology, Milan, Italy 3 A.O.R.N.A.S. “Garibaldi”, Operative Unit of Dermatology, Catania, Italy 4 Private Practitioner in Dermatology, Bari, Italy 5 Private Practitioner in Dermatology, Catania, Italy 6 Provate Practitioner in Dermatology, Milan, Italy 7 Private Practitioner in Dermatology, Pavia, Italy 8 Private Practitioner in Dermatology Istituto Oncologico Veneto (I.O.V.), Padua, Italy 9 Laboratoires Dermatologiques Uriage, Italy 10 Department of Dermatological Sciences University of Florence, Florence, Italy


AIM AND METHODS: The treatment of mild-moderate acne with topical drugs in association with appropriate cosmeceutics is currently the golden standard. The tolerability and efficacy of a cream formulated with a new mix of alpha-hydroxy acids (Hyseac AHA creamR) in 248 patients with mild-moderate acne (comedonic, inflammatory, or mixed) have been investigated in a multicenter, non-randomized, open study by 10 dermatologists from different Italian areas during their routine practice. The medication with Hyseac AHA creamR was prescribed at first consultation for 60 days, twice a day, either as a monotherapy (49.2% patients) or in association with a pharmacological treatment (50.2%). RESULTS: The tolerability was good to excellent in 92.3% patients, without significant differences between patients using AHA cream in monotherapy (90.0%) or associated with concomitant pharmacological treatment (97.6%). The efficacy was overall high in 64.2% patients, again without significant differences related to concomitant pharmacological treatment or not (64.8% vs. 63.3%) and/or the acne clinical type (comedonic vs. inflammatory vs. mixed: 69.2% vs. 66.7% vs. 58%).
CONCLUSION: The results of this study, while confirming the high tolerability and efficacy of this AHA cream in the treatment of mild/moderate acne, reasonably suggest its possible use also in monotherapy. Furthermore, its use can be reasonably hypothesized as a maintenance treatment after specific pharmacological treatment even in more severe acne types.

top of page